PMA device
cobas HPV
Roche Molecular Systems, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Apr 19, 2011, newest Jun 16, 2026Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
PMA pathway
Device trials
9
Naming "cobas HPV"
MAUDE reports
2
Brand "cobas HPV", since 2015
PubMed studies
154
Mentioning "cobas HPV"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing cobas HPV
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 15 decisions filed under this name.
- cobas HPVPMA supplement
P190028-S023 · Decided Jun 16, 2026 · 162 days after receipt · Normal 180 Day Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Older decisions: P100020-S055, P100020-S049, P100020-S025, P100020-S017, P100020-S008, P100020-S004, P100020-S003, P100020-S001, P100020
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "cobas HPV", any status and sponsor, newest update first.
- Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General PractitionerPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT02749110 · 308 participants · Start Aug 28, 2016 · Primary completion Aug 23, 2019
Device: Vaginal self-sampling brush · For: Malignant Tumor of Cervix; Cervical Intraepithelial Neoplasia
Sites: Herzeele, France
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "cobas HPV", and for the whole product code for context.
This brand
2 reports: 1 malfunction, 1 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
- COBAS HPV TESTMalfunction
2243471-2021-01545 · Received Jun 1, 2021 · Event dated Mar 30, 2021
Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Device problem as coded: False Negative Result; Incorrect, Inadequate or Imprecise Result or Readings; Output Problem
Patient problem as coded: Insufficient Information
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0846-2021 · Started Nov 19, 2020
Reason given: Dirty Lens May Cause Invalid or False Positive Results
Cause as FDA categorized it: Device Design · Device type: Kit, Dna Detection, Human Papillomavirus (MAQ)
Published research
The most relevant PubMed records for "cobas HPV"[tiab]. The summary above synthesizes these.
- Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
Gilbert L, Ratnam S, Jang D, et al. · Cancer Biomark · 2022
- Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood.
Naseri S, Young S, Cruz G, et al. · Obstet Gynecol · 2022Observational Study, Research Support, Non-U.S. Gov't
- Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
Dahlstrom KR, Sikora AG, Liu Y, et al. · Oral Oncol · 2023Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- Quality Control of Biospecimens in a Danish Clinical Cytology Biobank.
Ørnskov D, Waldstrøm M, Thomsen LT, et al. · Biopreserv Biobank · 2023
- High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting.
Fleider LA, de Los Ángeles Tinnirello M, Gómez Cherey F, et al. · PLoS One · 2023Research Support, Non-U.S. Gov't
- Evaluating HPV-negative CIN2+ in the ATHENA trial.
Petry KU, Cox JT, Johnson K, et al. · Int J Cancer · 2016Multicenter Study, Research Support, Non-U.S. Gov't
- Cobas HPV Genotyping of FNA Sample Supernatant and Frozen Section Scrapings of Suspected Head and Neck Cancer.
Jones KJ, Dougherty RE, Randolph M, et al. · Appl Immunohistochem Mol Morphol · 2023
- Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.
Saville M, Sultana F, Malloy MJ, et al. · J Clin Microbiol · 2019Evaluation Study, Research Support, Non-U.S. Gov't
- Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media.
Jang D, Ratnam S, Smieja M, et al. · Tumour Virus Res · 2021Research Support, Non-U.S. Gov't
- Evaluation of Cobas HPV and SeqHPV Assays in the Chinese Multicenter Screening Trial.
Du H, Duan X, Liu Y, et al. · J Low Genit Tract Dis · 2021Clinical Trial, Multicenter Study
- The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers.
He Y, Chen W, Guo Z, et al. · Epidemiol Infect · 2021Comparative Study, Evaluation Study
- Performance of AmpFire HPV assay on neck cervical lymph node aspirate and oropharyngeal samples.
Jang D, Shah A, Arias M, et al. · J Virol Methods · 2020Evaluation Study
Other devices of this type
Also filed under product code MAQ.
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.